MUC16 and ovarian cancer: One study by a team investigating models and ovarian cancer examined the added-value of serum CA-125 to the mathematical prediction models in differentiating between benign and malignant adnexal tumors and concluded that the measurement of serum CA-125 was unnecessary, especially in premenopausal women [32].